RGC
Roberts, Glore & Co Portfolio holdings
AUM
$342M
This Quarter Return
+1.61%
1 Year Return
+15.34%
3 Year Return
+56.21%
5 Year Return
+102.72%
10 Year Return
+238.78%
AUM
$328M
AUM Growth
+$328M
(-2.7%)
Cap. Flow
-$9.84M
Cap. Flow
% of AUM
-3%
Top 10 Holdings %
Top 10 Hldgs %
36.34%
Holding
213
New
5
Increased
48
Reduced
109
Closed
12
Top Buys
| 1 |
iShares MSCI EAFE ETF
EFA
|
$981K |
| 2 |
Vanguard S&P 500 ETF
VOO
|
$710K |
| 3 |
Novo Nordisk
NVO
|
$552K |
| 4 |
ASML
ASML
|
$492K |
| 5 |
Adams Diversified Equity Fund
ADX
|
$364K |
Top Sells
| 1 |
Berkshire Hathaway Class B
BRK.B
|
$1.71M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$1.18M |
| 3 |
Charles River Laboratories
CRL
|
$964K |
| 4 |
Apple
AAPL
|
$911K |
| 5 |
CVS Health
CVS
|
$647K |
Sector Composition
| 1 | Technology | 16.85% |
| 2 | Healthcare | 16.12% |
| 3 | Financials | 14.31% |
| 4 | Industrials | 8.77% |
| 5 | Communication Services | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Ambev
ABEV
$34.9B
| $80.3K | 0.02% |
34,480
| – | – |
|
202
Albemarle
ALB
$9.99B
| – | – |
-2,883
| Closed | -$248K |
|
|
203
Charles River Laboratories
CRL
$8.04B
| – | – |
-5,223
| Closed | -$964K |
|
|
204
CVS Health
CVS
$92.8B
| – | – |
-14,407
| Closed | -$647K |
|
205
Dell
DELL
$82.6B
| – | – |
-1,877
| Closed | -$216K |
|
206
First Solar
FSLR
$20.9B
| – | – |
-1,158
| Closed | -$204K |
|
207
Illumina
ILMN
$15.8B
| – | – |
-2,670
| Closed | -$357K |
|
208
Morningstar
MORN
$11.1B
| – | – |
-610
| Closed | -$205K |
|
209
Neurocrine Biosciences
NBIX
$13.8B
| – | – |
-1,492
| Closed | -$204K |
|
210
Organon & Co
OGN
$2.45B
| – | – |
-13,826
| Closed | -$206K |
|
211
T Rowe Price
TROW
$23.6B
| – | – |
-1,875
| Closed | -$212K |
|
212
UFP Industries
UFPI
$5.91B
| – | – |
-1,788
| Closed | -$201K |
|
213
United States Lime & Minerals
USLM
$3.61B
| – | – |
-2,300
| Closed | -$305K |
|